These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 18829744)

  • 1. Why do we not yet have a human immunodeficiency virus vaccine?
    Levine AJ
    J Virol; 2008 Dec; 82(24):11998-2000. PubMed ID: 18829744
    [No Abstract]   [Full Text] [Related]  

  • 2. Biomarkers of natural and vaccine immunity against HIV.
    Keane N; John M
    Biomark Med; 2011 Apr; 5(2):113-6. PubMed ID: 21473715
    [No Abstract]   [Full Text] [Related]  

  • 3. Systems biology in the development of HIV vaccines.
    Haddad EK; Pantaleo G
    Curr Opin HIV AIDS; 2012 Jan; 7(1):44-9. PubMed ID: 22156842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV immunology needs a new direction.
    Medzhitov R; Littman D
    Nature; 2008 Oct; 455(7213):591. PubMed ID: 18833256
    [No Abstract]   [Full Text] [Related]  

  • 5. Innate immunity in HIV infection and implications for vaccine design: a summary of the workshop held at the National Institute of Allergy and Infectious Diseases, Bethesda on February 25-26, 2010.
    Bansal GP; Leitner WW
    Vaccine; 2010 Dec; 28(52):8229-35. PubMed ID: 21073990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innate immune system damage in human immunodeficiency virus type 1 infection. Implications for acquired immunity and vaccine design.
    Howie S; Ramage R; Hewson T
    Am J Respir Crit Care Med; 2000 Oct; 162(4 Pt 2):S141-5. PubMed ID: 11029383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New finding on immune response to HIV Tat may contribute to vaccine, treatment.
    James JS
    AIDS Treat News; 2000 Sep; (351):4. PubMed ID: 12173551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systems biology in understanding HIV pathogenesis and guiding vaccine development.
    Sekaly R; Pulendran B
    Curr Opin HIV AIDS; 2012 Jan; 7(1):1-3. PubMed ID: 22134343
    [No Abstract]   [Full Text] [Related]  

  • 9. HIV regulatory and accessory proteins: new targets for vaccine development.
    Robert-Guroff M
    DNA Cell Biol; 2002 Sep; 21(9):597-8. PubMed ID: 12396601
    [No Abstract]   [Full Text] [Related]  

  • 10. An approach to vaccines against human immunodeficiency virus.
    Girard M; Barré-Sinoussi F; Van Der Ryst E; Fultz P
    AIDS Res Hum Retroviruses; 1996 Mar; 12(5):461-3. PubMed ID: 8882334
    [No Abstract]   [Full Text] [Related]  

  • 11. Developments in preclinical AIDS vaccine efficacy models.
    Bogers WM; Cheng-Mayer C; Montelaro RC
    AIDS; 2000; 14 Suppl 3():S141-51. PubMed ID: 11086857
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of the SIV model in AIDS vaccine research.
    Friedrich TC; Watkins DI
    IAVI Rep; 2005; 9(2):1, 6-8. PubMed ID: 16156073
    [No Abstract]   [Full Text] [Related]  

  • 13. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses.
    Abel K; Pahar B; Van Rompay KK; Fritts L; Sin C; Schmidt K; Colón R; McChesney M; Marthas ML
    J Virol; 2006 Jul; 80(13):6357-67. PubMed ID: 16775324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Animal studies of vaccine show promise.
    AIDS Patient Care STDS; 1998 May; 12(5):409. PubMed ID: 11361983
    [No Abstract]   [Full Text] [Related]  

  • 16. Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection.
    Horton H; Havenar-Daughton C; Lee D; Moore E; Cao J; McNevin J; Andrus T; Zhu H; Rubin A; Zhu T; Celum C; McElrath MJ
    J Virol; 2006 Oct; 80(19):9779-88. PubMed ID: 16973582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is required of an HIV vaccine?
    Bangham CR; Phillips RE
    Lancet; 1997 Nov; 350(9091):1617-21. PubMed ID: 9393353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV and SIV CTL escape: implications for vaccine design.
    Goulder PJ; Watkins DI
    Nat Rev Immunol; 2004 Aug; 4(8):630-40. PubMed ID: 15286729
    [No Abstract]   [Full Text] [Related]  

  • 19. A systems approach to understanding vaccines.
    von Bubnoff A
    IAVI Rep; 2010; 14(4):16-20. PubMed ID: 20857649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural Immunity to HIV: A Template for Vaccine Strategies.
    Fourcade L; Poudrier J; Roger M
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29690575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.